TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Newron Pharmaceuticals SpA ( (CH:NWRN) ).
Newron Pharmaceuticals has announced promising preclinical research results for Evenamide, a potential treatment for schizophrenia. The study, published in Neuropsychopharmacology, highlights Evenamide’s unique mechanism of action, targeting the hyperexcitability of the hippocampus, which could improve outcomes for patients who are treatment-resistant or inadequately responsive to current antipsychotics. This development represents a significant advancement in schizophrenia treatment, potentially offering a new therapeutic strategy that addresses positive, cognitive, and negative symptoms without the side effects associated with existing antipsychotics.
More about Newron Pharmaceuticals SpA
Newron Pharmaceuticals SpA is a biopharmaceutical company focused on developing novel therapies for central and peripheral nervous system disorders. Based in Bresso, near Milan, Italy, the company’s lead drug candidate is Evenamide, a first-in-class glutamate modulator, which is in clinical Phase III development for treatment-resistant schizophrenia and patients who respond inadequately to current therapies.
YTD Price Performance: -16.54%
Average Trading Volume: 35,375
Technical Sentiment Signal: Buy
Current Market Cap: CHF149.1M
For an in-depth examination of NWRN stock, go to TipRanks’ Overview page.